Special Issue

Glycans in Therapy and Diagnostics

Message from the Guest Editors

Glycans are a major constituent of glycolipids as well as secreted and cell surface glycoproteins and account for the overall structural microheterogeneity of these molecules. Human-type glycan structures are characterized by a set of individual glycan moieties composed of varying numbers of alvcosidically linked hexose and desoxyhexose units and neuraminic acid. Aberrant patterns of glycosylation have been observed in the context of several diseases and are therefore being developed into valuable biomarkers that help to distinguish a healthy from the diseased state and lift the power of diagnostic assays to yet another level. Glycan discovery, glycan engineering and glycan analytics are among the most important fields of current biopharma research. This Special Issue comprises expert contributions on glycans in the context of diagnostic biomarker discovery and development, glycan structure as a target for molecular engineering of production hosts for therapeutic glycoproteins and current advances in glycan analytical technology.

Guest Editors

Dr. Volker Sandig ProBioGen AG, Berlin, Germany

Prof. Dr. Hans Henning Von Horsten

Department of Engineering, HTW-Berlin University of Applied Sciences, 12459 Berlin, Germany

Prof. Dr. Stephan Hinderlich

Department of Life Sciences and Technology, Beuth University of Applied Sciences, 13353 Berlin, Germany

Deadline for manuscript submissions

closed (15 December 2022)



Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 5.3 Indexed in PubMed



mdpi.com/si/106659

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

mdpi.com/journal/bioengineering





Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 5.3 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

